Identification of <i>N</i>,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase InhibitorMaria Gabriella Brasca, Marina Ciomei, Nadia Amboldi et al.|Journal of Medicinal Chemistry|2009Cited by 128
CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled StudyBruno P. Imbimbo, Gabriella Bottini, M Franceschi et al.|Current Alzheimer Research|2013Cited by 78
Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor EfficacyClara Albanese, Marina Ciomei, Dario Ballinari et al.|Molecular Cancer Therapeutics|2010Cited by 63
Pharmacokinetics and Pharmacodynamics of CHF5074 After Short-term Administration in Healthy SubjectsBruno P. Imbimbo, Magdy Shenouda, E. Frigerio et al.|Alzheimer Disease & Associated Disorders|2012Cited by 37
Anti‐tumour efficacy on glioma models of <scp>PHA</scp>‐848125, a multi‐kinase inhibitor able to cross the blood–brain barrierClara Albanese, Marina Ciomei, Rachele Alzani et al.|British Journal of Pharmacology|2013Cited by 21